

# Contents

## Chapter 1. Introduction

1.1 Nanocarrier for Drug Delivery.....	1
1.2 Lipid Based Drug Delivery Systems (LBDDS).....	2
1.3 Drug candidate selection.....	3
1.4 Aims and Objectives.....	4
1.5 Hypothesis.....	4
1.6 Plan of Work.....	5

## Chapter 2. Literature Review

2.1 Oral Lipid based Formulations .....	8
2.2 Factors affecting oral bioavailability and LBDDS role to increase bioavailability .....	8
2.3 Digestion and absorption of lipids .....	12
2.4 Self Microemulsifying Drug Delivery System (SMEDDS) .....	13
2.5 Composition of SMEDDS .....	15
2.6 Pseudo-ternary phase diagram .....	17
2.7 Formulation development .....	18
2.8 Examples of studies related to SMEDDS for oral delivery .....	19
2.9 Niosomes.....	24
2.10 Formulation consideration for Niosomes.....	25
2.11 Formulation development .....	27
2.12 Examples of studies related to Niosomes .....	29
2.13 Drug Profile: ILOPERIDONE.....	32
2.14 Drug Profile: VARDENAFIL HCL TRIHYDRATE .....	39

## Chapter 3. Materials and Protocols

3.1 Sources of Chemicals.....	56
3.2 General protocols for Cell Cultures .....	60
3.3 General procedure for characterization techniques.....	62

## Chapter 4. Analytical Techniques

4.1 Materials .....	68
4.2 Analytical Methods .....	68
4.3 Analytical Techniques for Iloperidone .....	69
4.4 Analytical Techniques for Vardenafil HCl trihydrate .....	78
4.5 Estimation of residual solvents – Methanol and Chloroform by HS-GC .....	88

## Chapter 5. Experimental

5.1 Self Emulsifying Drug Delivery System - SMEDDS .....	93
5.2 Development of SMEDDS Formulations .....	93
5.3 Optimization of SMEDDS Formulations.....	95
5.4 Characterization of SMEDDS Formulations .....	99
5.5 Drug Release.....	102
5.6 Stability .....	103
5.7 NIOSOMES .....	104
5.8 Selection of method for Niosomes formulation development .....	105
5.9 Selection of surfactant.....	106
5.10 Drug-Excipient interaction studies by FTIR.....	106
5.11 Optimization .....	106
5.12 Lyophilization .....	108
5.13 Characterization of Niosomes Formulations .....	108
5.14 Drug Release.....	110
5.15 Stability .....	111

## Chapter 6. Results and Discussion

6.1 SMEDDS .....	117
6.2 ILO SMEDDS – Formulation development .....	117
6.3 ILO SMEDDS – Formulation optimization.....	123
6.4 ILO SMEDDS – Characterization .....	132
6.5 Drug release study.....	137
6.6 VDN SMEDDS – Formulation development .....	141
6.7 VDN SMEDDS – Formulation optimization.....	147

6.8 VDN SMEDDS preparation using Tween 20 as surfactant.....	158
6.9 VDN SMEDDS – Characterization .....	158
6.10 NIOSOMES – Formulation development.....	170
6.11 Preliminary Investigation for ILO Niosomes development.....	170
6.12 Optimization using OVAT approach .....	175
6.13 Design of Experiment – Combined D-optimal mixture design for optimization of ILO niosomes .....	180
6.14 VDN Niosomes development .....	192
6.15 Design of Experiment – Combined D-optimal mixture design for optimization of VDN niosomes .....	192
6.16 Optimization of Cryoprotectant for Lyophilization of ILO and VDN Niosomes .....	202
6.17 Characterization of ILO and VDN Niosomes.....	204

## Chapter 7. Cell Line Study

7.1 In vitro Cell Viability Study .....	220
7.2 Intracellular uptake study.....	221
7.3 Flow cytometry .....	221
7.4 In vitro permeability study.....	221
7.5 Actin Visualization .....	222
7.6 In vitro Cell Viability Study .....	223
7.7 Intracellular uptake study.....	225
7.8 Flow cytometry .....	228
7.9 In vitro permeability study.....	231
7.10 Actin Visualization .....	233

## Chapter 8. Animal Studies

8.1 Introduction.....	240
8.2 Animals.....	240
8.3 Pharmacokinetic study in Rats.....	240
8.4 Pharmacodynamic study for Schizophrenia.....	243
8.5 Pharmacodynamic study for Erectile dysfunction .....	246
8.6 Results and Discussion .....	250

## Chapter 9. Summary and Conclusion

9.1 Introduction.....	275
9.2 Aims and Objectives.....	275
9.3 SMEDDS .....	276
9.4 Niosomes.....	277
9.5 <i>In vitro</i> cell line studies.....	279
9.6 Animal Studies.....	281
9.7 Conclusions.....	284